KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Assets for 13 consecutive years, with $633.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 20.67% to $633.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $633.2 million, a 20.67% decrease, with the full-year FY2025 number at $633.2 million, down 20.67% from a year prior.
  • Assets was $633.2 million for Q4 2025 at Xenon Pharmaceuticals, up from $607.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $964.8 million in Q4 2023 to a low of $264.4 million in Q3 2021.
  • A 5-year average of $671.7 million and a median of $702.4 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: soared 202.35% in 2021, then dropped 27.28% in 2025.
  • Xenon Pharmaceuticals' Assets stood at $572.0 million in 2021, then surged by 31.84% to $754.1 million in 2022, then rose by 27.93% to $964.8 million in 2023, then fell by 17.27% to $798.1 million in 2024, then dropped by 20.67% to $633.2 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Assets are $633.2 million (Q4 2025), $607.8 million (Q3 2025), and $674.3 million (Q2 2025).